Article Text

Download PDFPDF
Review: cardioselective β blockers do not produce adverse respiratory effects in COPD

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with chronic obstructive pulmonary disease (COPD), do cardioselective β blockers cause adverse respiratory effects?

Clinical impact ratings GP/FP/Primary care ★★★★★★★ IM/Ambulatory care ★★★★★☆☆ Cardiology ★★★★★★☆ Respirology ★★★★★★☆


Embedded ImageData sources

Cochrane Central Register of Controlled Trials, Medline, EMBASE/Excerpta Medica, CINAHL, respiratory journals, meeting abstracts, and relevant references (up to May 2005).

Embedded ImageStudy selection and assessment

randomised, blinded, controlled trials (RCTs) in any language that evaluated cardioselective β blockers as a single dose or for an extended period in patients with COPD and reported change in FEV1 or respiratory symptoms. Administration of β2 agonists, either intravenously or by inhalation, after cardioselective β blockers or placebo, was also studied. 20 RCTs (all crossover trials) met the selection criteria. 11 trials (n = 131, mean age 53.8 y, 80% men) evaluated a single dose of …

View Full Text


  • For correspondence: Dr S Salpeter, Stanford University and Santa Clara Valley Medical Center, San Jose, CA, USA. shelley.salpeter{at}

  • Source of funding: Garfield Weston Foundation UK.